Private Investors Diary Portfolio

John Rosier takes the plunge with a trio of high expectation shares

John Rosier reviews the lessons learnt in 2018 and explains why he is comfortable starting the new year fully invested

John Rosier is taking a sanguine view of market gyrations, using deratings to work for, rather than against, him

The rising oil price has helped John Rosier's portfolio recover after a difficult start to the year

John Rosier turns to a few simple rules to create a new 20-stock portfolio he hopes will successfully capture their upwards rerating

It's difficult to ignore the powerful factors driving the world towards a robotics future. John Rosier is increasing his exposure to this next big phase in technological change

It pays to react quickly and firmly to early warning signs, says John Rosier

John Rosier discards a sizeable Europe holding in favour of an attractively priced UK medical specialist

The portfolio's performance is up on the first quarter, but it is still lagging the All-Share – time in the market, not timing the market is key

John Rosier, prompted by the Conviviality fiasco, has cut his losers and found some stimulating new investments with a strong bull case behind them

John Rosier explains why he's aiming to build up exposure to companies that are benefiting from advances in technology

The FTSE bore the brunt of a sharp global sell-off in January, but diarist John Rosier isn’t too worried by the correction

John Rosier reviews the recent strong performance of his portfolio and explains how he plans to drive performance in 2018

Our private investor diarist John Rosier explains why he’s shunning a shift to cash and remains fully invested

Our diarist John Rosier thinks the biotech sector is being judged too harshly by investors

Our private investor diarist, John Rosier, explains how investment trusts have been the biggest contributor to his returns this year

Our private investor diarist John Rosier’s portfolio’s good run continued through August, helped along by a five-bagger biotech

John Rosier's portfolio is performing strongly, helped by his mid- and small-cap holdings. But should he hold fewer stocks?

John Rosier updates investors on the six-month performance of his portfolio